Compare DIN & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DIN | FULC |
|---|---|---|
| Founded | 1958 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 399.8M | 467.8M |
| IPO Year | 1994 | 2019 |
| Metric | DIN | FULC |
|---|---|---|
| Price | $35.23 | $3.84 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $29.00 | $16.38 |
| AVG Volume (30 Days) | 358.1K | ★ 3.4M |
| Earning Date | 05-06-2026 | 04-27-2026 |
| Dividend Yield | ★ 2.78% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $879,300,000.00 | N/A |
| Revenue This Year | $3.61 | N/A |
| Revenue Next Year | $0.64 | N/A |
| P/E Ratio | $62.54 | ★ N/A |
| Revenue Growth | ★ 8.25 | N/A |
| 52 Week Low | $19.58 | $2.83 |
| 52 Week High | $39.68 | $15.74 |
| Indicator | DIN | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 59.62 | 41.39 |
| Support Level | $33.47 | $2.83 |
| Resistance Level | $36.06 | $4.02 |
| Average True Range (ATR) | 1.49 | 0.23 |
| MACD | 0.03 | 0.14 |
| Stochastic Oscillator | 66.21 | 70.09 |
Dine Brands Global Inc owns and franchises thousands of restaurants under the International House of Pancakes (IHOP), Applebee's Neighborhood Grill + Bar (Applebee's), and the Fuzzy's Taco Shop (Fuzzy's) names. The company conducts its business through three reportable segments: Franchise, Company-owned restaurants, and Rental. The majority of its revenue is generated from the Franchise segment, which consists of IHOP, Applebee's, and Fuzzy's franchise operations and generates revenue mainly from royalties and advertising fees from several IHOP, Applebee's, and Fuzzy's franchised restaurants, in addition to revenues from the sale of proprietary IHOP and Fuzzy's products to its franchisees. Geographically, the majority of the company's revenues is generated from its domestic market.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.